EXPLORE THE SCIENCE
TL;DR: A 2026 preprint in medRxiv found that treatment-resistant depression affected 34% of medication-exposed major-depression patients in Pakistan’s DIVERGE study, with social support and CYP2C19 metabolizer status standing out as locally important treatment…
Read article
TL;DR: A 2026 study in The Pharmacogenomics Journal tested pharmacogenomic (PGx) depression care, meaning medication guidance based on drug-gene interactions; targeting Veterans already taking antidepressants with common PGx interactions raised the actionable-…
Read article
TL;DR: A 2026 methylome-wide study in Clinical Epigenetics found that genetically inferred CYP2C19 metaboliser status, a pharmacogenomic marker relevant to antidepressant handling, was associated with DNA methylation patterns in a large Scottish cohort. Key Fi…
Read article
CYP2C19 poor metabolizers showed a nominally higher antidepressant remission rate compared to normal metabolizers, but overall genetic variations in CYP2C19 and CYP2D6 were not significantly associated with antidepressant response. Highlights: Higher Remission…
Read article
Researchers have made strides towards enabling personalized dosing for the commonly prescribed antidepressant escitalopram. Using robust clinical trial data, they developed an innovative population pharmacokinetics model that elucidates the impact of patient g…
Read article